2
|
Fujimoto Y, Nakanishi R, Nukatsuka M, Matsuoka K, Ando K, Wakasa T, Kitao H, Oki E, Maehara Y, Mori M. Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. Cancer Chemother Pharmacol 2020; 85:1029-1038. [PMID: 32322913 DOI: 10.1007/s00280-020-04072-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2019] [Accepted: 04/04/2020] [Indexed: 12/11/2022]
Abstract
PURPOSE Trifluridine (FTD) is the active component of the nucleoside chemotherapeutic drug trifluridine/tipiracil (FTD/TPI), which is approved worldwide for the treatment of patients with metastatic gastrointestinal cancer. FTD exerts cytotoxic effects via its incorporation into DNA, but FTD has not been detected in the tumor specimens of patients. The purpose of this study was to detect FTD in tumors resected from metastatic colorectal cancer (mCRC) patients who were administered FTD/TPI. Another purpose was to investigate the turnover rate of FTD in tumors and bone marrow in a mouse model. METHODS Tumors and normal tissue specimens were obtained from mCRC patients who were administered FTD/TPI or placebo at Kyushu University Hospital. Tumors and bone marrow were resected from mice with peritoneal dissemination treated with FTD/TPI. To detect and quantitate FTD incorporated into DNA, immunohistochemical staining of paraffin-embedded specimens (IHC-p staining) and slot-blot analysis of DNA purified from these tissues were performed using an anti-BrdU antibody. IHC-p staining of proliferation and apoptosis markers was also performed. RESULTS FTD was detected in metastatic tumors obtained from mCRC patients who were administered FTD/TPI, but who had discontinued the treatment several weeks before surgery. In a peritoneal dissemination mouse model, FTD was still detected in tumors 13 days after the cessation of FTD/TPI treatment, but had disappeared from bone marrow within 6 days. CONCLUSION These results indicate that FTD persists longer in tumors than in bone marrow, which may cause a sustained antitumor effect with tolerable hematotoxicity.
Collapse
Affiliation(s)
- Yoshiaki Fujimoto
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Ryota Nakanishi
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Mamoru Nukatsuka
- Translational Research Laboratory, Taiho Pharmaceutical Co. Ltd., Tokushima, Japan
| | - Kazuaki Matsuoka
- Translational Research Laboratory, Taiho Pharmaceutical Co. Ltd., Tokushima, Japan
| | - Koji Ando
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Takeshi Wakasa
- Translational Research Laboratory, Taiho Pharmaceutical Co. Ltd., Tokushima, Japan
- Department of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
| | - Hiroyuki Kitao
- Department of Molecular Cancer Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
| | - Eiji Oki
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Yoshihiko Maehara
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan
| | - Masaki Mori
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
3
|
Iwano J, Shinmi D, Masuda K, Murakami T, Enokizono J. Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies. Drug Metab Dispos 2019; 47:1240-1246. [PMID: 31533926 DOI: 10.1124/dmd.119.088179] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Accepted: 08/22/2019] [Indexed: 01/13/2023] Open
Abstract
Carcinoembryonic antigen (CEA) is a tumor-specific antigen overexpressed in multiple cancers. CEA is expressed as a membrane protein, a part of which is cleaved from the cell membrane and secreted into blood. The soluble form of CEA (sCEA) has been shown to accelerate the clearance of anti-CEA antibody, which limits the antibody distribution in the tumor. To overcome this issue, we developed an anti-CEA monoclonal antibody, 15-1-32, which shows a strong affinity for membrane-bound CEA (mCEA) and relatively weak affinity for sCEA. In this study, we compared the effect of sCEA on the pharmacokinetics of 15-1-32 in mice with that of another anti-CEA monoclonal antibody, labetuzumab, showing less selectivity to mCEA than 15-1-32. As expected, the effect of sCEA on the serum concentration of 15-1-32 was much smaller than that of labetuzumab. The decrease in the area under the curve (AUC) of serum concentration was 22.5% for 15-1-32 when it was coadministered with sCEA, while that of labetuzumab was 79.9%. We also compared the pharmacokinetics of these two antibodies in CEA-positive tumor-bearing mice. The AUCs of 15-1-32 and labetuzumab were decreased in tumor-bearing mice compared with non-tumor-bearing mice to a similar extent (approximately 40% decrease). These results suggested that mCEA also contributes to the clearance of anti-CEA antibodies in CEA-positive tumor-bearing mice. Although the increased selectivity to mCEA minimized the effect of sCEA on the pharmacokinetics of 15-1-32, it may be insufficient to improve the pharmacokinetics in CEA-positive cancer patients. SIGNIFICANCE STATEMENT: Because previous studies reported the rapid clearance of anti-CEA antibodies mediated by soluble CEA, we obtained a monoclonal antibody, 15-1-32, selective to membrane-bound CEA and evaluated the effects of CEA on its pharmacokinetics. Although the effect of soluble CEA on the serum concentration of 15-1-32 was very small, the clearance of 15-1-32 in CEA-positive tumor-bearing mice was still rapid, suggesting membrane-bound CEA also contributes to the clearance of anti-CEA antibodies. These results indicated that increasing selectivity to membrane-bound CEA is not enough to improve the pharmacokinetics of anti-CEA antibody.
Collapse
Affiliation(s)
- Junko Iwano
- Nucleic Acid Medicine Research Laboratories, Research Functions Unit, R&D Division (J.I.), Bio Process Research and Development Laboratories, Production Division (D.S.), Oncology Research Laboratories, Oncology R&D Unit, R&D Division (K.M.), and Pharmacokinetics Research Laboratories, Translational Research Unit, R&D Division (J.E.), Kyowa Hakko Kirin Co., Ltd., Tokyo; and Department of Microbiology, Faculty of Medicine, Saitama Medical University, Saitama (T.M.), Japan
| | - Daisuke Shinmi
- Nucleic Acid Medicine Research Laboratories, Research Functions Unit, R&D Division (J.I.), Bio Process Research and Development Laboratories, Production Division (D.S.), Oncology Research Laboratories, Oncology R&D Unit, R&D Division (K.M.), and Pharmacokinetics Research Laboratories, Translational Research Unit, R&D Division (J.E.), Kyowa Hakko Kirin Co., Ltd., Tokyo; and Department of Microbiology, Faculty of Medicine, Saitama Medical University, Saitama (T.M.), Japan
| | - Kazuhiro Masuda
- Nucleic Acid Medicine Research Laboratories, Research Functions Unit, R&D Division (J.I.), Bio Process Research and Development Laboratories, Production Division (D.S.), Oncology Research Laboratories, Oncology R&D Unit, R&D Division (K.M.), and Pharmacokinetics Research Laboratories, Translational Research Unit, R&D Division (J.E.), Kyowa Hakko Kirin Co., Ltd., Tokyo; and Department of Microbiology, Faculty of Medicine, Saitama Medical University, Saitama (T.M.), Japan
| | - Takashi Murakami
- Nucleic Acid Medicine Research Laboratories, Research Functions Unit, R&D Division (J.I.), Bio Process Research and Development Laboratories, Production Division (D.S.), Oncology Research Laboratories, Oncology R&D Unit, R&D Division (K.M.), and Pharmacokinetics Research Laboratories, Translational Research Unit, R&D Division (J.E.), Kyowa Hakko Kirin Co., Ltd., Tokyo; and Department of Microbiology, Faculty of Medicine, Saitama Medical University, Saitama (T.M.), Japan
| | - Junichi Enokizono
- Nucleic Acid Medicine Research Laboratories, Research Functions Unit, R&D Division (J.I.), Bio Process Research and Development Laboratories, Production Division (D.S.), Oncology Research Laboratories, Oncology R&D Unit, R&D Division (K.M.), and Pharmacokinetics Research Laboratories, Translational Research Unit, R&D Division (J.E.), Kyowa Hakko Kirin Co., Ltd., Tokyo; and Department of Microbiology, Faculty of Medicine, Saitama Medical University, Saitama (T.M.), Japan
| |
Collapse
|